IP Library › Patent Application 13383796
Patent Application
App. No. 13/383,796

COMPOSITION AND METHOD FOR MAINTENANCE, DIFFERENTIATION, AND PROLIFERATION OF STEM CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/383,796
Abstract

Compositions and methods for the proliferation, differentiation, and maintenance of stem cells are described. Preferred are the use of hematopoietic stem cells in combination with a collagen matrix.

Claims (26)

1 . A method for maintaining or proliferating hematopoietic stem cells in vitro, said method comprising the steps of:

contacting an hematopoietic stem cell population with an engineered collagen matrix; and

maintaining or proliferating the hematopoietic stem cells in vitro.

2 . The method of claim 1 wherein the collagen matrix has a fibril density of about 5% to about 30%, and wherein the collagen matrix has a storage modulus of about 10 Pa to about 3200 Pa.

3 . The method of claim 1 further comprising the step of contacting said matrix with osteoblasts.

4 . The method of claim 3 wherein the osteoblasts enhance proliferation or maintenance of the hematopoietic stem cells.

5 . The method of claim 1 wherein the matrix has a storage modulus of about 10 Pa to about 100 Pa.

6 . The method of claim 1 wherein the matrix has a storage modulus of about 500 Pa to about 2000 Pa.

7 . The method of claim 1 wherein the matrix has a storage modulus of about 700 Pa to about 1500 Pa.

8 . The method of claim 1 wherein the matrix has a storage modulus of about 700 Pa to about 900. Pa.

9 . The method of claim 8 wherein the hematopoietic stem cells are undifferentiated.

10 .- 11 . (canceled)

12 . The method of claim 8 wherein the hematopoietic stem cell population exhibits clonogenic potential.

13 .- 18 . (canceled)

19 . A composition comprising hematopoietic stem cells and an engineered collagen matrix.

20 . The composition of claim 19 further comprising osteoblasts.

21 . The composition of claim 19 wherein the collagen matrix has a fibril density of about 5% to about 30%, and wherein the collagen matrix has a storage modulus of about 10 Pa to about 3200 Pa.

22 . The composition of claim 20 wherein the osteoblasts enhance proliferation or function of the hematopoietic stem cells.

23 . The composition of claim 19 wherein the matrix has a storage modulus of about 10 Pa to about 100 Pa.

24 . The composition of claim 19 wherein the matrix has a storage modulus of about 500 Pa to about 2000 Pa.

25 . The composition of claim 19 wherein the matrix has a storage modulus of about 700 Pa to about 900 Pa.

26 . The composition of claim 25 wherein the hematopoietic stem cells are undifferentiated.

27 . The composition of claim 25 wherein the hematopoietic stem cell population exhibits expression of an hematopoietic stem cell marker.

28 . (canceled)

29 . The composition of claim 25 wherein the hematopoietic stem cell population exhibits clonogenic potential.

30 .- 64 . (canceled)

Assignments (2)
SECURITY INTEREST Recorded Apr 30, 2024
From: CROSMAN CORPORATION
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 067275/0210 →
CONFIRMATORY LICENSE Recorded Mar 21, 2013
From: INDIANA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030055/0460 →